Healthy Clinical Trial
— BIOLIVAOfficial title:
Table Olives Nutritional Intervention: Pharmacokinetics of Polyphenols and Pentacyclic Triterpenes and Assessment of Antioxidant, Cardiovascular and Anti-inflammatory Biomarkers
Verified date | August 2019 |
Source | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Olives and olive oil are typical components of the Mediterranean diet being part of its cultural and gastronomic heritage. Since ancient times, olives have been used either for both, oil extraction or whole fruit consumption as table olives. Olive oil stands out from both the nutritional and the health point of view. However, the effect of table olives consumption remains almost unknown. The beneficial properties of olive oil have been initially ascribed to the high concentration of oleic acid. Nowadays, these positive effects have been attributed also to minor compounds such as polyphenols or pentacyclic triterpenes. Table olives contain a higher amount of both polyphenols and pentacyclic triterpenes than their oil, with the same healthy fatty acid profile. Therefore, the present intervention aims at investigating the pharmacokinetic of polyphenols and pentacyclic triterpenes after a single olive intake as well as the assessment of the effect of the consumption of olives during 30 days on the overall health status playing particular attention to the anti-inflammatory, antioxidant and cardiovascular biomarkers.
Status | Completed |
Enrollment | 58 |
Est. completion date | June 15, 2019 |
Est. primary completion date | May 25, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Body Mass Index between 19 and 30 kg/m2. - Healthy on the basis of physical examination and routine biochemical and hematological laboratory determinations. - Free acceptance to participate in the study by obtains signed informed consent. Exclusion Criteria: - Smoking. - Alcohol or drug abuse. - Heavy consumer of stimulating beverages (>5 coffees, teas, chocolate or cola drinks per day) and grapefruit juice. - Background of allergy, idiosyncrasy or hypersensitivity to drugs. - Intake of any medication within 2 weeks prior taking the study intervention (except for use of paracetamol in short-term symptomatic treatments), including over-the-counter products (including natural food supplements, vitamins and medicinal plants products), or any enzymatic inductor or inhibitor within 3 months before the drug administration. - Positive serology for hepatitis B, C or HIV. - Background or clinical evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematological or neurological disease or other chronic diseases. - Having undergone major surgery during the previous 6 months. - Pregnancy or lactation status (if applied). - Participation in another clinical trial during the 3 months preceding the drug administration. - Donation of blood during the 4 weeks preceding the drug administration. - Acute illness four weeks before drug administration. |
Country | Name | City | State |
---|---|---|---|
Spain | Institut de Recerca Hospital de la Santa Creu i Sant Pau - CIM Sant Pau | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Ministerio de Economía y Competitividad (Spain) AGL 2013-41188R, University of Barcelona |
Spain,
Bachhav SS, Bhutada MS, Patil SP, Sharma KS, Patil SD. Oleanolic Acid Prevents Increase in Blood Pressure and Nephrotoxicity in Nitric Oxide Dependent Type of Hypertension in Rats. Pharmacognosy Res. 2014 Oct-Dec;7(4):385-92. doi: 10.4103/0974-8490.159575. — View Citation
Cicerale S, Conlan XA, Sinclair AJ, Keast RS. Chemistry and health of olive oil phenolics. Crit Rev Food Sci Nutr. 2009 Mar;49(3):218-36. doi: 10.1080/10408390701856223. Review. — View Citation
Covas MI, Nyyssönen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, Gaddi A, de la Torre R, Mursu J, Bäumler H, Nascetti S, Salonen JT, Fitó M, Virtanen J, Marrugat J; EUROLIVE Study Group. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 2006 Sep 5;145(5):333-41. — View Citation
de la Torre-Carbot K, Chávez-Servín JL, Jaúregui O, Castellote AI, Lamuela-Raventós RM, Fitó M, Covas MI, Muñoz-Aguayo D, López-Sabater MC. Presence of virgin olive oil phenolic metabolites in human low density lipoprotein fraction: determination by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chim Acta. 2007 Feb 5;583(2):402-10. Epub 2006 Nov 2. — View Citation
Dzubak P, Hajduch M, Vydra D, Hustova A, Kvasnica M, Biedermann D, Markova L, Urban M, Sarek J. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep. 2006 Jun;23(3):394-411. Epub 2006 May 3. Review. — View Citation
Ghanbari R, Anwar F, Alkharfy KM, Gilani AH, Saari N. Valuable nutrients and functional bioactives in different parts of olive (Olea europaea L.)-a review. Int J Mol Sci. 2012;13(3):3291-340. doi: 10.3390/ijms13033291. Epub 2012 Mar 12. Review. — View Citation
Juan ME, Planas JM, Ruiz-Gutierrez V, Daniel H, Wenzel U. Antiproliferative and apoptosis-inducing effects of maslinic and oleanolic acids, two pentacyclic triterpenes from olives, on HT-29 colon cancer cells. Br J Nutr. 2008 Jul;100(1):36-43. doi: 10.1017/S0007114508882979. Epub 2008 Feb 26. — View Citation
Kountouri AM, Mylona A, Kaliora AC, Andrikopoulos NK. Bioavailability of the phenolic compounds of the fruits (drupes) of Olea europaea (olives): impact on plasma antioxidant status in humans. Phytomedicine. 2007 Oct;14(10):659-67. Epub 2007 Sep 17. — View Citation
Liu J, Sun H, Duan W, Mu D, Zhang L. Maslinic acid reduces blood glucose in KK-Ay mice. Biol Pharm Bull. 2007 Nov;30(11):2075-8. — View Citation
Lou-Bonafonte JM, Arnal C, Navarro MA, Osada J. Efficacy of bioactive compounds from extra virgin olive oil to modulate atherosclerosis development. Mol Nutr Food Res. 2012 Jul;56(7):1043-57. doi: 10.1002/mnfr.201100668. Review. — View Citation
Lozano-Mena G, Sánchez-González M, Juan ME, Planas JM. Maslinic acid, a natural phytoalexin-type triterpene from olives--a promising nutraceutical? Molecules. 2014 Aug 4;19(8):11538-59. doi: 10.3390/molecules190811538. Review. — View Citation
Madlala HP, Van Heerden FR, Mubagwa K, Musabayane CT. Changes in Renal Function and Oxidative Status Associated with the Hypotensive Effects of Oleanolic Acid and Related Synthetic Derivatives in Experimental Animals. PLoS One. 2015 Jun 5;10(6):e0128192. doi: 10.1371/journal.pone.0128192. eCollection 2015. — View Citation
Marrugat J, Covas MI, Fitó M, Schröder H, Miró-Casas E, Gimeno E, López-Sabater MC, de la Torre R, Farré M; SOLOS Investigators. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial. Eur J Nutr. 2004 Jun;43(3):140-7. Epub 2004 Jan 6. — View Citation
Martín-Peláez S, Covas MI, Fitó M, KuĊĦar A, Pravst I. Health effects of olive oil polyphenols: recent advances and possibilities for the use of health claims. Mol Nutr Food Res. 2013 May;57(5):760-71. doi: 10.1002/mnfr.201200421. Epub 2013 Mar 1. Review. — View Citation
Melliou E, Zweigenbaum JA, Mitchell AE. Ultrahigh-pressure liquid chromatography triple-quadrupole tandem mass spectrometry quantitation of polyphenols and secoiridoids in california-style black ripe olives and dry salt-cured olives. J Agric Food Chem. 2015 Mar 11;63(9):2400-5. doi: 10.1021/jf506367e. Epub 2015 Feb 26. — View Citation
Poudyal H, Campbell F, Brown L. Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr. 2010 May;140(5):946-53. doi: 10.3945/jn.109.117812. Epub 2010 Mar 24. — View Citation
Rodriguez-Rodriguez R, Perona JS, Herrera MD, Ruiz-Gutierrez V. Triterpenic compounds from "orujo" olive oil elicit vasorelaxation in aorta from spontaneously hypertensive rats. J Agric Food Chem. 2006 Mar 22;54(6):2096-102. — View Citation
Sánchez-Quesada C, López-Biedma A, Warleta F, Campos M, Beltrán G, Gaforio JJ. Bioactive properties of the main triterpenes found in olives, virgin olive oil, and leaves of Olea europaea. J Agric Food Chem. 2013 Dec 18;61(50):12173-82. doi: 10.1021/jf403154e. Epub 2013 Nov 22. Review. — View Citation
Uylaser V, Yildiz G. The historical development and nutritional importance of olive and olive oil constituted an important part of the Mediterranean diet. Crit Rev Food Sci Nutr. 2014;54(8):1092-101. doi: 10.1080/10408398.2011.626874. — View Citation
Weinbrenner T, Fitó M, de la Torre R, Saez GT, Rijken P, Tormos C, Coolen S, Albaladejo MF, Abanades S, Schroder H, Marrugat J, Covas MI. Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men. J Nutr. 2004 Sep;134(9):2314-21. — View Citation
* Note: There are 20 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Stage 1: Maximum plasma concentration (Cmax) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Concentration at the end of the dosing interval (Ct) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Time until Cmax is reached (Tmax) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Area under the curve from administration to last observed concentration at time (AUC (0-t) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: AUC extrapolated to infinite time (AUC (0-8) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Percentage of AUC extrapolated (AUC%) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Terminal elimination rate constant (Kel) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Plasma concentration half-life (t ½) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Volume of distribution (Vd/ F) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Clearance (Cl/F) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Peak trough fluctuation over one dosing interval at steady state (PTF) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Cmax dose normalized (Cmax/Dose) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: AUC (0-t) dose normalized (AUC (0-t)/Dose) | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Urine polyphenols concentration | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 1: Urine triterpenes concentration | 24 hour dosing period; 2 dosing periods each separated by 7 days washout | 24 hours | |
Primary | Stage 2: Plasma polyphenols concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Plasma triterpenes concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Urine polyphenols concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Urine triterpenes concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Malondialdehyde concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Catalase concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Glutathione peroxidase concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Superoxide dismutase concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: F2A isoprostane concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: 8 isoprostane concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Oxidized low-density lipoprotein concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: C-Reactive Protein concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Lipoprotein-associated phospholipase A2 concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Apolipoprotein A1 concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Apolipoprotein B100 concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Tumor necrosis factor alpha concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Interleukin 6 concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Primary | Stage 2: Interleukin 1 concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 1 and 2: Number of participants with treatment-related adverse events | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 1 and 2: Systolic and diastolic blood pressure | Stage 1: 24 hours, Stage 2: 30 days | Stage 1: 24 hour dosing period; 2 dosing periods each separated by 7 days washout, Stage 2: 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 1 and 2: Heart rate | Stage 1: 24 hours, Stage 2: 30 days | Stage 1: 24 hour dosing period; 2 dosing periods each separated by 7 days washout, Stage 2: 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 1 and 2: Respiratory rate | Stage 1: 24 hours, Stage 2: 30 days | Stage 1: 24 hour dosing period; 2 dosing periods each separated by 7 days washout, Stage 2: 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Body weight | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: High-density lipoprotein cholesterol concentration (HDL-C) | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Low-density lipoprotein cholesterol concentration (LDL-C) | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Very low-density lipoprotein cholesterol concentration (VLDL-C) | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Triglyceride concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Total cholesterol concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Sodium concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Glucose concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Urea concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Creatinine concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Aspartate aminotransferase concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Alanine aminotransferase concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Alkaline phosphatase concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout | |
Secondary | Stage 2: Total proteins concentration | 30 days | 30 days dosing period or 30 days as control group separated by 15 days washout |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |